The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Beneficial Effects of Probiotic Bifidobacterium and Galacto-Oligosaccharide in Patients with Ulcerative Colitis: A Randomized Controlled Study
Abstract
Background/Aim: In previous studies, we described the beneficial effects of bifidobacteria-fermented milk in patients with ulcerative colitis (UC). Here, we examined the effects of a live Bifidobacterium breve strain Yakult, a probiotic contained in bifidobacteria-fermented milk, and galacto-oligosaccharide (GOS) as synbiotics in UC patients. Methods: Forty-one patients with mild to moderate UC were assigned to two groups; one group was treated with the synbiotics and the other was not (control). The treatment group ingested 1 g of the probiotic powder (109 CFU/g) three times a day, and 5.5 g of GOS once a day for one year. At the start and the end of this study, colonoscopic index and the amount of myeloperoxidase in a lavage solution were used as disease activity indices. Bacterial counts in the feces at the start and the end of this study were also examined. Results: After a one-year treatment with the synbiotics, the clinical status of the UC patients as assessed by colonoscopy, significantly improved. Furthermore, the amount of myeloperoxidase in the lavage also decreased in these patients after the synbiotic treatment. The synbiotics significantly reduced the fecal counts of Bacteroidaceae and fecal pH. Conclusion: Administration of live B. breve strain Yakult and GOS can improve the clinical condition of patients with UC. These results encouraged us to perform a large-scale randomized, placebo-controlled trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the two strains of B. breve included in the table were tested together with some of these bacteria [139,141] , or even with prebiotics such as galacto-oligosaccharides [140]”
From Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis (2014) · cites this paper as [140]
Citations
Cites
AFRC, R. F. (1989) · Journal of Applied Bacteriology · doi:10.1111/j.1365-2672.1989.tb05105.x · Cited by 4,831
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’Neil, D. A., & Macfarlane, G. T. (2005) · Gut · doi:10.1136/gut.2004.044834 · Cited by 766
VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis
Bibiloni, R., Fedorak, R. N., Tannock, G. W., Madsen, K. L., Gionchetti, P., Campieri, M., Simone, C. D., & Sartor, R. B. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41794.x · Cited by 743
Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397
Self-citationG Protein-Coupled Receptor 43 Is Essential for Neutrophil Recruitment during Intestinal Inflammation
Sina, C., Gavrilova, O., Förster, M., Till, A., Derer, S., Hildebrand, F., Rabe, B., Chalaris, A., Scheller, J., Rehmann, A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900063 · Cited by 385
A pilot trial of Saccharomyces boulardii in ulcerative colitis
Guslandi, M., Giollo, P., & Testoni, P. A. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200306000-00017 · Cited by 383
Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis
Ishikawa, H., Akedo, I., Umesaki, Y., Tanaka, R., Imaoka, A., & Otani, T. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719276 · Cited by 369
Self-citationEarly administration of Bifidobacterium breve to preterm infants: randomised controlled trial
Kitajima, H., Sumida, Y., Tanaka, R., Yuki, N., Takayama, H., & Fujimura, M. (1997) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.76.2.f101 · Cited by 315
Self-citation
Cited by
Sorted by citations
Bifidobacteria and Their Role as Members of the Human Gut Microbiota
O’Callaghan, A. A., & van Sinderen, D. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00925 · Cited by 1,160
Actinobacteria: A relevant minority for the maintenance of gut homeostasis
Binda, C., Lopetuso, L. R., Rizzatti, G., Gibiino, G., Cennamo, V., & Gasbarrini, A. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.02.012 · Cited by 828
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
ESPEN guideline: Clinical nutrition in inflammatory bowel disease
Forbes, A., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.027 · Cited by 625
RetractedIntestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
Tojo, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15163 · Cited by 533
Metadata
- Authors
- Ishikawa, H., Matsumoto, S., Ohashi, Y., Imaoka, A., Setoyama, H., Umesaki, Y., Tanaka, R., & Otani, T.
- Affiliations
- Kyoto Prefectural University of Medicine (JP)
- Yakult Central Institute (JP)
- Osaka International Cancer Institute (JP)
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 84
- Issue
- 2
- Pages
- 128-133
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- OpenAlex
- W2050226660
- Cited by
- 197
- References
- 25
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 19 · 2023: 16 · 2022: 14 · 2021: 21 · 2020: 19 · 2019: 15 · 2018: 14 · 2017: 17 · 2016: 11 · 2015: 11 · 2014: 14 · 2013: 4 · 2012: 7
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Digestion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Keywords
- ulcerative colitis, Bifidobacterium breve, Yakult, galactooligosaccharides, synbiotics, probiotics, myeloperoxidase, fecal pH, disease activity, colonoscopy
- MeSH terms
- Adult, Bifidobacterium, Colitis, Ulcerative, Colonoscopy, Feces, Female, Humans, Male, Middle Aged, Peroxidase, Oligosaccharides, Severity of Illness Index, Probiotics, Prebiotics, Synbiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
